

# **Applications of Transcranial Doppler Ultrasonography in Sickle Cell Disease, Stroke, and Critical Illness in Children**

Kerri L. LaRovere and Nicole F. O'Brien

# **Background**

Since the 1980s, TCD has remained the gold standard stroke risk prediction tool in children with sickle cell disease (SCD) by identifying those who benefit from blood transfusion  $[1-5]$  $[1-5]$ . The rigor of this prior research and impact of TCD on the health of children with SCD has remained unmatched to date in other pediatric populations. Results largely from single center, small pediatric studies, and precedent from adult neurocritical care, however, suggest that use of TCD in critically ill children may have promise. According to a survey of 27 centers in the United States with an expert interest in pediatric neurocritical care (PNCC), TCD was

N. F. O'Brien  $(\boxtimes)$ 

K. L. LaRovere

Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA e-mail[: kerri.larovere@childrens.harvard.edu](mailto:kerri.larovere@childrens.harvard.edu)

Department of Pediatrics, The Ohio State University/Nationwide Children's Hospital, Columbus, OH, USA e-mail[: Nicole.obrien@nationwidechildrens.org](mailto:Nicole.obrien@nationwidechildrens.org)

being applied in the PICU for a variety of conditions including: traumatic brain injury (TBI), hypoxic-ischemic encephalopathy (HIE) following cardiac arrest, arterial ischemic stroke, subarachnoid hemorrhage, cerebral vascular malformation, hepatic encephalopathy, sepsis, and diabetic ketoacidosis (DKA). Importantly, TCD seemed to direct clinical care in 75% of the contributing PICUs in this survey [[6\]](#page-13-1). In acute care settings like the PICU and pediatric emergency department (ED), TCD has several potential roles: as a point of care ultrasound (POCUS) study to rapidly diagnose disorders of cerebral perfusion and incorporate fndings into clinical decisions in an aim to improve clinical care and outcomes; and as a continuous non-invasive neuromonitoring tool alone or integrated with multi-modal monitoring systems.

There are a number of barriers that must be overcome, however, before TCD can be used in a safe, meaningful, and effective way in pediatric acute care. First and foremost, normal values with a clear understanding of variability due to age, gender, type of critical illness, and associated therapies are needed [[7,](#page-13-2) [8\]](#page-13-3). Although there is a reasonable starting point for normative values in healthy children and in those sedated and mechanically ventilated, the main limitation of these prior studies is the small sample size for each age category [\[8](#page-13-3), [9](#page-13-4)]. Normative data for healthy children are available in Table [1](#page-2-0) [\[8](#page-13-3)]. In the absence of reliable normative data, abnormal TCD fndings in critically ill children should be treated as hypothesis-generating. Secondly, large cohort studies are needed to validate TCD fndings in children against an acceptable gold standard (e.g. imaging studies, measurements of absolute intracranial pressure [ICP] from invasive ICP monitors), to determine the appropriate clinical indications for the performance of TCD, and to quantify the impact of TCD fndings on clinical care and outcomes. Finally, there are several technical challenges to overcome in order to achieve consistent results in children including: properly ftting, safe, and comfortable headgear for uninterrupted signal acquisition; standardized performance of the TCD examination in the PICU for reproducible and verifable waveforms; and examiner expertise in the care of criti-

Age	<b>MCA</b>	<b>ICA</b>	<b>ACA</b>	<b>PCA</b>	<b>BA</b>
Systolic peak velocity:					
$0 - 10$ days	46(10)	47(9)	35(8)	$\qquad \qquad -$	
$11-90$ days	75(15)	77 (19)	58 (15)	$\overline{\phantom{0}}$	
$3-11.9$ months	114(20)	104(12)	77(15)	$\overline{a}$	
$1-2.9$ years	124(10)	118(24)	81 (19)	69(9)	71 (6)
$3-5.9$ years	147(17)	144 (19)	104(22)	81 (16)	88 (9)
$6-9.9$ years	143(13)	140(14)	100(20)	75(10)	85(17)
$10-18$ years	129(17)	125(18)	92(19)	66 (10)	68 (11)
Mean flow velocity <sup>a</sup> :					
$0 - 10$ days	24(7)	25(6)	19(6)	$\qquad \qquad -$	
$11-90$ days	42(10)	43(12)	33(11)	$\overline{\phantom{0}}$	
$3-11.9$ months	74(14)	67(10)	50(11)	$\overline{\phantom{0}}$	
$1-2.9$ years	85 (10)	81(8)	55(13)	50(12)	51(6)
$3-5.9$ years	94 (10)	93(9)	71(15)	48(11)	58 (6)
$6-9.9$ years	97(9)	93(9)	65(13)	51(9)	58 (9)
$10-18$ years	81(11)	79 (12)	56 (14)	45(9)	46(8)
End diastolic peak velocity:					
$0-10$ days	12(7)	12(6)	10(6)	$\qquad \qquad -$	—
$11-90$ days	24(8)	24(8)	19(9)	—	
$3-11.9$ months	46(9)	40(8)	33(7)	$\qquad \qquad -$	-
$1-2.9$ years	65(11)	58(5)	40(11)	35(7)	35(6)
$3-5.9$ years	65(9)	66(8)	48 (9)	35(9)	41(5)
$6-9.9$ years	72(9)	68 (10)	51(10)	38(7)	44(8)
$10-18$ years	60(8)	59(9)	46(11)	33(7)	36(7)

<span id="page-2-0"></span>**Table 1** Normative transcranial doppler ultrasound values by age (mean (SD) [[8\]](#page-13-3)

*MCA* Middle Cerebral Artery, *ICA* Internal Carotid Artery, *ACA* Anterior Cerebral Artery, *PCA* Posterior Cerebral Artery, *BA* Basilar Artery a Mean Flow Velocity = time mean of the maximal velocity envelope curve

cally ill children for appropriate interpretation and integration of the waveforms into clinical decision making.

In this chapter we will review some potential emerging clinical applications for TCD in children recognizing that these limitations must be resolved before TCD can be put into clinical practice. We will focus on: frst, childhood stroke and arteriopathies; and

293

second, those applications that may be well suited for children in the critical care setting including traumatic brain injury (TBI), cerebral vasospasm, monitoring during extracorporeal membrane oxygenation (ECMO), and brain death. The content of this chapter is relevant not only for providers in PNCC (e.g. intensivists, neurologists, anesthesiologists), but also for radiologists who have an interest in this predominantly non-sickle cell population.

#### **Childhood Stroke and Arteriopathies**

#### **Sickle Cell Disease (SCD) in Children**

SCD is a group of genetic disorders that result in production of hemoglobin S. Under conditions of cellular stress, hemoglobin S polymerizes, distorts the shape of red blood cells, and leads to irreversible sickling. Sickled cells have a reduced life span, which leads to an intravascular hemolytic anemia, and can cause occlusion of the microvasculature, which is believed to be the major cause of the wide range of clinical symptoms. The largest inception cohort study demonstrated an alarming stroke rate of nearly 12% by age 18 years [\[10\]](#page-13-5). Stroke mechanisms in children with SCD are likely multifactorial and include: microvascular occlusion as occurs in the systemic circulation; endothelial injury from a potential cellmediated infammatory vasculopathy and/or a potential role for platelet and/or monocyte dysfunction; and reduced nitric oxide bioavailability from chronic hemolysis and excess plasma free hemoglobin (nitric oxide has anti-infammatory and anti-thrombotic properties) [[11,](#page-13-6) [12\]](#page-13-7). Angiographic series and pathologic studies support a large artery occlusive vasculopathy as the major contributor to ischemic stroke in children with SCD [\[13](#page-13-8)[–17\]](#page-13-9).

In the 1980s, Dr. Robert J Adams used a vessel-based approach with TCD to stratify stroke risk in children with SCD. The key fndings from his series of studies were: (1) TCD could distinguish children with SCD from those without SCD [[18\]](#page-13-10); (2) TCD could detect stenotic lesions as seen on angiography and distinguish children with SCD with stenosis from those without steno-

sis [[19\]](#page-13-11); and (3) stroke risk could be stratifed by the time averaged mean of the maximum fow velocity (TAMMX) in the middle cerebral artery (MCA) or internal carotid artery (ICA) such that children with TAMMX in either artery ≥200 cm/s had a 40% risk of a frst ever stroke within 3 years [[1,](#page-12-0) [20\]](#page-14-0).

In the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study, 1934 children with SCD from age 2 to 16 years old were screened with TCD at 14 clinic sites in the United States. Children with mean flow velocity  $>200$  cm/s in the MCA or ICA were randomized into two groups. Sixty-three children received regular blood transfusions every 3–4 weeks to maintain their hemoglobin S level ≤30% (intervention arm). Sixty-seven children received standard care with periodic blood transfusions (control group). The main fnding was a 10% yearly stroke rate in the control group compared to  $a < 1\%$  stroke rate in the intervention arm, indicating a 92% relative risk reduction for a frst ever stroke  $(p < 0.001)$  [[2\]](#page-12-1). Based on the results of this study, current guidelines recommend that children between ages 2 years and 16 years with sickle cell disease should be screened with TCD annually if the study is normal (TAMMX in the MCA or ICA <170 cm/s), and quarterly if conditional (TAMMX 170–199 cm/s). Regular blood transfusions should be initiated for an abnormal TCD (TAMMX in least one artery  $>200$  cm/s) [[21\]](#page-14-1).

# **Other Childhood Arteriopathies**

Children with moyamoya syndrome present with ischemic stroke or transient ischemic attack due to chronic and progressive stenoses involving the arteries in the anterior cerebral circulation. Based on adult data, there may be a role for TCD as an adjunct to angiography in children with moya-moya syndrome [\[22](#page-14-2)]. However, validation of cerebral blood flow velocity (CBFV) thresholds in moyamoya in children that suggests clinically relevant stenoses do not exist. Rather, in children with angiographic evidence of vascular occlusion or stenosis, CBFVs may be followed over time once baseline data are procured to monitor for worsening of disease.

Children with focal cerebral arteriopathy (FCA) may be differentiated from moyamoya or cerebral vasculitis by a clinical course of improvement or stabilization over time, occasionally after a period of initial worsening. Acute central nervous system (CNS) infections from bacterial infections and herpesvirus can be associated with the development of FCA and arterial ischemic stroke in children [[23–](#page-14-3)[25](#page-14-4)]. While stroke mechanisms in FCA remain unclear, vessel diameter narrowing (stenosis and/or vasospasm) from contact of exudate with the vessel wall may play a role. While vascular changes are best characterized by angiography, this diagnostic study often has to be repeated frequently over weeks to months after the acute illness and may require repeated sedation and/or endotracheal intubation in young children. TCD may have a preferred role in long-term monitoring of this disease if a correlation with angiography is found.

# **Pediatric Critical Care Applications**

#### **Moderate to Severe TBI**

In adults, TCD criteria for hypoperfusion following severe TBI have been used to guide early resuscitation [\[26](#page-14-5), [27\]](#page-14-6). Similar criteria for children, however, remain unclear. In a study by Trabold et al. of 36 children with moderate to severe TBI, end diastolic cerebral blood fow velocity (Vd) <25 cm/second and pulsatility index (PI) >1.31 after the frst resuscitation in the ED was associated with poor outcome, defned as Glasgow Outcome Scale 3–5 at hospital discharge (Vd: AUROC  $0.91 \pm 0.02$ , p = 0.03; PI: AUROC  $0.89 \pm 0.02$ , p = 0.04) [[28\]](#page-14-7). It is important to note that in this study, mortality rate was high at 11%, and the study was not powered to perform multivariate analyses on variables besides TCD measurements, such as the Glasgow Coma Scale and other injury severity scores, that may be independent factors of poor prognosis. Other investigators have attempted to discover relationships between CBFVs and outcome, but these studies are limited by small sample sizes, retrospective study design, and lack of rigorous, serial protocol-driven TCD measurements [[29–](#page-14-8) [31](#page-14-9)]. More individual level and rigorous data collection and analyses are needed.

In children with moderate to severe TBI, there has also been some work on the use of TCD for non-invasive ICP and cerebral perfusion pressure (CPP) estimation. TCD is an attractive alternative to invasive monitoring in children for 2 reasons: (1) the recommendation in the 2019 updated guidelines for management of severe TBI in children can only support class III evidence for ICP monitoring [[32,](#page-14-10) [33](#page-15-0)]; and (2) there is low utilization of gold standard invasive ICP monitoring in children [[34–](#page-15-1)[39\]](#page-15-2). Similar to the adult literature, Vd and PI are not reliable indicators of increased ICP in children when compared to gold standard invasive ICP measurements [[28,](#page-14-7) [40–](#page-15-3)[42\]](#page-15-4). The main limitations in these studies are that PI measurements were often made as single, point source measurements at different timepoints following the injury in small numbers of children. A continuous, fully automated, real-time engineering approach using synchronized systemic arterial blood pressure and MCA waveforms has been recently shown to estimate ICP with similar accuracy and precision as routinely used invasive ICP monitors [[43\]](#page-15-5). Validation in larger cohorts is needed. Regarding the use of TCD to estimate CPP (CPPe) in children with severe TBI, use of the formula CPPe = ABPmean\*FVd (diastolic flow velocity)/Fvm (mean flow velocity)  $+14$  as a regression equation gives limits of agreement of −17 to +25 mmHg, which is not clinically acceptable [\[44](#page-15-6)].

#### **Cerebral Vasospasm**

Cerebral vasospasm is a reversible reduction in the caliber of an arterial lumen of a vessel in the subarachnoid space. Arterial narrowing leads to an increase in TCD derived CBFVs and a decrease in PI with worsening spasm. If severe, vasospasm can lead to a critical reduction in cerebral blood fow and cerebral ischemia. Cerebral vasospasm has been reported following resection of brain tumors, ruptured cerebral aneurysms and arteriovenous malformations, CNS infections, and moderate to severe TBI in chil-

dren [[29,](#page-14-8) [45](#page-16-0)[–51](#page-16-1)]. The diagnostic accuracy of TCD for angiographic proven vasospasm when adult criteria are used in children is low, with a positive likelihood ratio of only 2.0 [[52\]](#page-16-2). Using adult criteria in pediatrics has such a low positive likelihood ratio because CBFVs are higher in children compared to adults across all age groups [[53\]](#page-16-3). The pediatric literature to date on this topic is limited by the use of adult criteria, lack of radiographic confrmation of elevated CBFVs and Lindegaard ratios, and small sample sizes. Thus, validated TCD thresholds for vasospasm do not exist for children. Prospective studies comparing age-related CBFV measurements and Lindegaard ratios to angiographic data in children with symptomatic vasospasm are needed. In the absence of robust pediatric data, TCD should be used as a precursor to defnitive imaging when there is a suspicion for vasospasm (e.g. persistent increase in CBFVs over time, or signifcant day to day changes in CBFVs). Figure [1](#page-7-0) is an example of a representative case where TCD was used to assist in the diagnosis and management of a child with cerebral vasospasm.

<span id="page-7-0"></span>

**Fig. 1** 24-month-old female involved in a motor vehicle accident. Transcranial Doppler ultrasound (TCD) was normal on days 1–3, but on post-injury day 4, right middle cerebral artery fow increased to 220 cm/sec with an LR of 6.9. Neurologic status declined with new left sided hemiparesis. Based on results of the TCD, angiogram was ordered and confrmed the diagnosis of cerebral vasospasm. Therapeutic interventions were undertaken, and neurologic examination improved. TCD was repeated daily with no further worsening of vasospasm and normalization of fow by post-injury day 7. Therapies were weaned with no worsening of TCD flow velocities

#### **Monitoring During ECMO**

Detection of acute brain injury that is clinically recognizable or in the subclinical phase during ECMO in a sedated and/or paralyzed child is diffcult. To date, what is known about the relevance of CBFV measurements in children is that similar to adults, CBFVs and PI are lower in children supported on ECMO during the frst 5 days of therapy in those who do not have acute brain injury [\[54](#page-16-4)]. Serial TCD monitoring has not, however, shown a reliable correlation between changes in velocity and brain ischemia or hemorrhage [\[54](#page-16-4), [55](#page-16-5)]. Larger studies in this population are needed. At present, the only reliable way to detect acute brain injury during ECMO is "after the fact" by serial neurologic exams with confrmation of focal neurologic deficits by neuroimaging.

ECMO is a life-saving treatment for heart and/or lung failure, as a bridge to transplant, or as an aid to cardiopulmonary resuscitation for in hospital cardiac arrest. The use of ECMO has quadrupled in children in the last 15 years to >2500 cases in 2016 [[56\]](#page-16-6). ECMO technology has improved so that avoiding acute brain injury during the course of ECMO is now key to survival and better long-term outcomes [\[57](#page-17-0)[–61](#page-17-1)]. Acute brain injury occurs in the form of hypoxic ischemic injury, intracranial hemorrhage, and arterial ischemic stroke. Data supporting the use and effectiveness of current neuromonitoring methods on ECMO to detect acute brain injury is limited. The majority of the evidence for monitoring using neuroimaging, electroencephalography (EEG), cerebral oximetry, serum biomarkers and Doppler ultrasound is limited to mainly level 3B (case-control) and 4 (case series).

Cerebral emboli, representing air or solid matter, are one potential cause of acute brain injury during ECMO. Emboli may occur as a result of low cardiac output, or direct passage of emboli in the systemic circulation from the ECMO circuit or left heart chambers [\[62](#page-17-2)[–64](#page-17-3)]. TCD can detect emboli as distinct high intensity signals (HITS) or microembolic signals (MES) in the Doppler spectrum. Although consensus on their signature exists in the Doppler spectrum [[65\]](#page-17-4), emboli monitoring has not transitioned into routine clinical care in children for the following reasons: (1) sparse pediatric literature; (2) commercial TCD software seems to generate excess false positive events and better event separation is needed

<span id="page-9-0"></span>

**Fig. 2** 7-month-old male undergoing TCD monitoring during cardiopulmonary bypass for complex congenital heart disease repair. Multiple highintensity signals were noted throughout the case. The events were of unknown clinical signifcance as patient did not have any gross neurologic defcits on hospital discharge

 $[66]$  $[66]$ ; (3) manual review is laborious and time consuming; and (4) uninterrupted signal acquisition remains a challenge due to the lack of appropriately sized headgear for infants and young children. Further technical improvements are needed to distinguish the true embolic count, size, and composition of embolic events. As a starting point to generate further data, emboli monitoring may be appropriate for infants and children on cardiopulmonary bypass while undergoing cardiac surgery [\[67](#page-17-6)]. Figure [2](#page-9-0) represents embolic phenomenon identifed by TCD in a child on cardiopulmonary bypass for repair of congenital heart disease.

# **Brain Death**

Unlike adults, standards and guidelines for the TCD diagnosis of cerebral circulatory arrest do not exist for children. There are >10 cases reported in the literature of children from birth to 11 months who met clinical (loss of brainstem refexes) and EEG criteria for brain death, but cerebral blood flow by angiography and/or TCD was detected [\[68,](#page-17-7) [69\]](#page-17-8). One reason for these findings may be that the elastic infant skull with open fontanelles can oppose rising ICP, allowing

301

for signifcant increases in cranial volume without a reduction in CPP (risk of false negative). False positives, on the other hand, may occur due to operator inexperience and misinterpretation of "absent" flow in infants who normally have a low diastolic flow velocity  $(12 \pm 7 \text{ cm/s})$ sec). Accordingly, TCD is not currently recommended as an ancillary test to aid in brain death determination in children <18 years. TCD may, however, indicate the optimal timing for a perfusion study if there is clinical diagnostic uncertainty of brain death [\[70\]](#page-17-9). Figure [3](#page-10-0) represents the use of TCD in a child suffering traumatic brain injury to direct timing of confrmatory brain death testing.

<span id="page-10-0"></span>

**Fig. 3** 8-year-old male suffering severe traumatic brain injury following a motor vehicle collision. Panel A represents his admission TCD with near normal peak systolic velocities but with fattened diastolic fow and a modestly high pulsatility index. Intracranial pressure (ICP) was 29 mmHg during the TCD examination. Despite maximal medical and surgical management, ICP continued to increase to 60 mmHg by hospital day 3. Clinical examination was concerning for brain death, but apnea testing could not be performed due to hypoxia secondary to bilateral pulmonary contusions and lacerations. Panel B represents TCD images of the middle cerebral artery acquired on hospital day 3. Trace diastolic fow was noted. Thus, given the uncertain diagnostic certainty of a confrmatory perfusion study at that time in a patient who was not clinically stable, it was deferred. Panel C represents TCD images of the middle cerebral artery acquired on hospital day 4. Systolic spikes with complete lack of diastolic fow were noted and brain death was confrmed with perfusion study following the TCD examination



**Fig. 3** (continued)

# **Other Conditions**

One last potential unique application of TCD may be as a screening tool to aid in clinical decisions and guide therapy in children in low income countries with cerebral malaria (CM). Malaria is a global health problem resulting in >400,000 deaths annually, twothirds of which occur in children under age 5 years [\[71](#page-17-10)]. CM is a severe manifestation of malaria and can be diagnosed when the child presents in coma with Plasmodium parasitemia and no other identifable cause for coma (such as hypoglycemia, seizures, or meningitis). Severe neurologic disability (e.g. weakness/paralysis, hypotonia, spasticity, speech and language disorders, movement and gait disorders, vision impairment, epilepsy, and behavioral problems) is present in about one half of survivors [\[72](#page-18-0)]. Even with excellent clinical care, the mortality rate from CM is approximately 15% [[73\]](#page-18-1).

In a prospective observational study performed at 3 clinical sites in the Democratic Republic of the Congo between 2015 and 2017, O'Brien et al. found 5 different TCD "phenotypes" in 160 children with CM during the frst 8 days of hospital admission. Interestingly, a total of 151/160 patients remained in one of the following phenotypic categories until normalization or death: hyperemia was seen in 42 cases  $(26\%)$ , low flow state in 46 cases (28%), microvascular obstruction in 35 cases (22%), and cerebral vasospasm in 21 cases (13%) [\[50](#page-16-7)]. Validation of pathophysiologic mechanisms associated with each TCD phenotype may aid in the development of individual targeted adjunctive therapies that may improve outcomes for children with CM.

# **Conclusions**

TCD has an established clinical role in reducing a frst ever stroke in children with SCD by identifying those who are high risk and beneft from blood transfusion. Beyond sickle cell disease, other potential roles for TCD are as a point of care ultrasound or neuromonitoring strategy in the PICU setting. TCD data in critically ill children should be treated as hypothesis-generating. TCD may serve as a precursor or adjunct to defnitive imaging or invasive techniques. Collaboration and research is needed to advance the TCD feld in pediatrics.

# **References**

- <span id="page-12-0"></span>1. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605–10.
- <span id="page-12-1"></span>2. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a frst stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.
- 3. Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19(1):110–29.
- 4. Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, et al. Stroke and conversion to high risk in children screened with transcranial doppler ultrasound during the STOP study. Blood. 2004;103(10):3689–94.
- <span id="page-13-0"></span>5. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia trial I: discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–78.
- <span id="page-13-1"></span>6. LaRovere KL, Tasker RC, Wainwright M, Reuter-Rice K, Appavu B, Miles D, et al. Transcranial doppler ultrasound during critical illness in children: survey of practices in pediatric neurocritical care centers. PCCM. 2020;21(1):67–74.
- <span id="page-13-2"></span>7. Tegeler CH, Crutchfeld K, Katsnelson M, Kim J, Tang R, Passmore Griffn L, et al. Transcranial doppler velocities in a large, healthy population. J Neuroimaging. 2013;23(3):466–72.
- <span id="page-13-3"></span>8. O'Brien NF. Reference values for cerebral blood fow velocities in critically ill sedated children. Childs Nerv Syst. 2015;31(12):2269–76.
- <span id="page-13-4"></span>9. Bode H, Wais U. Age dependence of fow velocities in basal cerebral arteries. Arch Dis Child. 1988;63(6):606–11.
- <span id="page-13-5"></span>10. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023–7.
- <span id="page-13-6"></span>11. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 1986;20(6):684–90.
- <span id="page-13-7"></span>12. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear fow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86(9): 3356–60.
- <span id="page-13-8"></span>13. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke. 1978;9(1):45–52.
- 14. Thust SC, Burke C, Siddiqui A. Neuroimaging fndings in sickle cell disease. Br J Radiol. 2014;87(1040):20130699.
- 15. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. NEJM. 1972;287(17):846–9.
- 16. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461–71.
- <span id="page-13-9"></span>17. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood. 1984;63(1):162–9.
- <span id="page-13-10"></span>18. Brass LM, Pavlakis SG, DeVivo D, Piomelli S, Mohr JP. Transcranial doppler measurements of the middle cerebral artery. Effect of hematocrit. Stroke. 1988;19(12):1466–9.
- <span id="page-13-11"></span>19. Adams RJ, Nichols FT, Figueroa R, McKie V, Lott T. Transcranial doppler correlation with cerebral angiography in sickle cell disease. Stroke. 1992;23(8):1073–7.
- <span id="page-14-0"></span>20. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial doppler. Ann Neurol. 1997;42(5):699–704.
- <span id="page-14-1"></span>21. Nichols FT, Jones AM, Adams RJ. Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial doppler testing. J Neuroimaging. 2001;11(4):354–62.
- <span id="page-14-2"></span>22. Lee YS, Jung KH, Roh JK. Diagnosis of moyamoya disease with transcranial doppler sonography: correlation study with magnetic resonance angiography. J Neuroimaging. 2004;14(4):319–23.
- <span id="page-14-3"></span>23. Fullerton HJ, Elkind MS, Barkovich AJ, Glaser C, Glidden D, Hills NK, et al. The vascular effects of infection in pediatric stroke (VIPS) study. J Child Neurol. 2011;26(9):1101–10.
- 24. Wintermark M, Hills NK, deVeber GA, Barkovich AJ, Elkind MS, Sear K, et al. Arteriopathy diagnosis in childhood arterial ischemic stroke: results of the vascular effects of infection in pediatric stroke study. Stroke. 2014;45(12):3597–605.
- <span id="page-14-4"></span>25. Elkind MS, Hills NK, Glaser CA, Lo WD, Amlie-Lefond C, Dlamini N, et al. Herpesvirus infections and childhood arterial ischemic stroke: results of the VIPS study. Circulation. 2016;133(8):732–41.
- <span id="page-14-5"></span>26. van Santbrink H, Schouten JW, Steyerberg EW, Avezaat CJ, Maas AI. Serial transcranial doppler measurements in traumatic brain injury with special focus on the early posttraumatic period. Acta Neurochir. 2002;144(11):1141–9.
- <span id="page-14-6"></span>27. Ract C, Le Moigno S, Bruder N, Vigue B. Transcranial doppler ultrasound goal-directed therapy for the early management of severe traumatic brain injury. Int Care Med. 2007;33(4):645–51.
- <span id="page-14-7"></span>28. Trabold F, Meyer PG, Blanot S, Carli PA, Orliaguet GA. The prognostic value of transcranial doppler studies in children with moderate and severe head injury. Int Care Med. 2004;30(1):108–12.
- <span id="page-14-8"></span>29. Chaiwat O, Sharma D, Udomphorn Y, Armstead WM, Vavilala MS. Cerebral hemodynamic predictors of poor 6-month Glasgow outcome score in severe pediatric traumatic brain injury. J Neurotrauma. 2009;26(5):657–63.
- 30. Visocchi M, Chiaretti A, Genovese O, Di Rocco F. Haemodynamic patterns in children with posttraumatic diffuse brain swelling. A preliminary study in 6 cases with neuroradiological features consistent with diffuse axonal injury. Acta Neurochir. 2007;149(4):347–56.
- <span id="page-14-9"></span>31. O'Brien NF, Maa T, Moore-Clingenpeel M, Rosenberg N, Yeates KO. Relationships between cerebral flow velocities and neurodevelopmental outcomes in children with moderate to severe traumatic brain injury. Childs Nerv Syst. 2018;34(4):663–72.
- <span id="page-14-10"></span>32. Kochanek PM, Tasker RC, Carney N, Totten AM, Adelson PD, Selden NR, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the brain trauma foundation guidelines. PCCM. 2019;20(3S Suppl 1):S1–S82.
- <span id="page-15-0"></span>33. Kochanek PM, Tasker RC, Carney N, Totten AM, Adelson PD, Selden NR, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the brain trauma foundation guidelines, executive summary. Neurosurgery. 2019;84(6):1169–78.
- <span id="page-15-1"></span>34. Alkhoury F, Kyriakides TC. Intracranial pressure monitoring in children with severe traumatic brain injury: National Trauma Data Bank-Based Review of outcomes. JAMA Surg. 2014, Jun;149(6):544–8.
- 35. Alali AS, Gomez D, Sathya C, Burd RS, Mainprize TG, Moulton R, et al. Intracranial pressure monitoring among children with severe traumatic brain injury. J Neurosurg Pediatr. 2015;16(5):523–32.
- 36. Morris KP, Forsyth RJ, Parslow RC, Tasker RC, Hawley CA, Group UKPTBIS, Paediatric Intensive Care Society Study G. Intracranial pressure complicating severe traumatic brain injury in children: monitoring and management. Int Care Med. 2006;32(10):1606–12.
- 37. Bennett TD, Riva-Cambrin J, Keenan HT, Korgenski EK, Bratton SL. Variation in intracranial pressure monitoring and outcomes in pediatric traumatic brain injury. Arch Pediatr Adolesc Med. 2012;166(7):641–7.
- 38. Dixon RR, Nocera M, Zolotor AJ, Keenan HT. Intracranial pressure monitoring in infants and young children with traumatic brain injury. PCCM. 2016;17(11):1064–72.
- <span id="page-15-2"></span>39. Van Cleve W, Kernic MA, Ellenbogen RG, Wang J, Zatzick DF, Bell MJ, et al. National variability in intracranial pressure monitoring and craniotomy for children with moderate to severe traumatic brain injury. Neurosurgery. 2013;73(5):746–52.
- <span id="page-15-3"></span>40. Figaji AA, Zwane E, Fieggen AG, Siesjo P, Peter JC. Transcranial doppler pulsatility index is not a reliable indicator of intracranial pressure in children with severe traumatic brain injury. Surg Neurol. 2009;72(4):389– 94.
- 41. Melo JR, Di Rocco F, Blanot S, Cuttaree H, Sainte-Rose C, Oliveira-Filho J, et al. Transcranial doppler can predict intracranial hypertension in children with severe traumatic brain injuries. Childs Nerv Syst. 2011;27(6):979–84.
- <span id="page-15-4"></span>42. O'Brien NF, Maa T, Reuter-Rice K. Noninvasive screening for intracranial hypertension in children with acute, severe traumatic brain injury. J Neurosurg Pediatr. 2015;16(4):420–5.
- <span id="page-15-5"></span>43. Fanelli A, Vonberg FW, LaRovere KL, Walsh BK, Smith ER, Robinson S, et al. Fully automated, real-time, calibration-free, continuous noninvasive estimation of intracranial pressure in children. J Neurosurg Pediatr. 2019;24(5):509–19.
- <span id="page-15-6"></span>44. O'Brien NF, Lovett ME, Chung M, Maa T. Non-invasive estimation of cerebral perfusion pressure using transcranial doppler ultrasonography in children with severe traumatic brain injury. Childs Nerv Syst. 2020;36(9):2063–71.
- <span id="page-16-0"></span>45. Rao VK, Haridas A, Nguyen TT, Lulla R, Wainwright MS, Goldstein JL. Symptomatic cerebral vasospasm following resection of a medulloblastoma in a child. Neurocrit Care. 2013;18(1):84–8.
- 46. Pendharkar AV, Guzman R, Dodd R, Cornfeld D, Edwards MS. Successful treatment of severe cerebral vasospasm following hemorrhage of an arteriovenous malformation. Case report. J Neurosurg Pediatr. 2009;4(3):266–9.
- 47. O'Brien NF, Reuter-Rice KE, Khanna S, Peterson BM, Quinto KB. Vasospasm in children with traumatic brain injury. Int Care Med. 2010;36(4):680–7.
- 48. O'Brien NF, Maa T, Yeates KO. The epidemiology of vasospasm in children with moderate-to-severe traumatic brain injury. CCM. 2014;43(3):674–85.
- 49. Philip S, Chaiwat O, Udomphorn Y, Moore A, Zimmerman JJ, Armstead W, et al. Variation in cerebral blood flow velocity with cerebral perfusion pressure >40 mm Hg in 42 children with severe traumatic brain injury. CCM. 2009;37(11):2973–8.
- <span id="page-16-7"></span>50. O'Brien NF, Mutatshi Taty T, Moore-Clingenpeel M, Bodi Mabiala J, Mbaka Pongo J, Ambitapio Musungufu D, et al. Transcranial doppler ultrasonography provides insights into neurovascular changes in children with cerebral malaria. Pediatrics. 2018;203(116–24):e113.
- <span id="page-16-1"></span>51. Garg K, Singh PK, Sharma BS, Chandra PS, Suri A, Singh M, et al. Pediatric intracranial aneurysms--our experience and review of literature. Childs Nerv Syst. 2014;30(5):873–83.
- <span id="page-16-2"></span>52. Moftakhar P, Cooke DL, Fullerton HJ, Ko NU, Amans MR, Narvid JA, et al. Extent of collateralization predicting symptomatic cerebral vasospasm among pediatric patients: correlations among angiography, transcranial doppler ultrasonography, and clinical fndings. J Neurosurg Pediatr. 2015;15(3):282–90.
- <span id="page-16-3"></span>53. Udomphorn Y, Armstead WM, Vavilala MS. Cerebral blood fow and autoregulation after pediatric traumatic brain injury. Pediatr Neurol. 2008;38(4):225–34.
- <span id="page-16-4"></span>54. O'Brien NF, Buttram SDW, Maa T, Lovett ME, Reuter-Rice K, LaRovere KL. Cerebrovascular physiology during pediatric extracorporeal membrane oxygenation: a multicenter study using transcranial doppler ultrasonography. PCCM. 2019;20(2):178-86.
- <span id="page-16-5"></span>55. Rilinger JF, Smith CM, deRegnier RAO, Goldstein JL, Mills MG, Reynolds M, et al. Transcranial doppler identifcation of neurologic injury during pediatric extracorporeal membrane oxygenation therapy. J Stroke Cerebrovasc Dis. 2017;26(10):2336–45.
- <span id="page-16-6"></span>56. Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal life support organization registry international report 2016. ASAIO. 2017;63(1):60–7.
- 57. Bembea MM, Felling RJ, Caprarola SD, Ng DK, Tekes A, Boyle K, et al. Neurologic outcomes in a two-center cohort of neonatal and pediatric

patients supported on extracorporeal membrane oxygenation. ASAIO. 2020;66(1):79–88.

- 58. Barrett CS, Bratton SL, Salvin JW, Laussen PC, Rycus PT, Thiagarajan RR. Neurological injury after extracorporeal membrane oxygenation use to aid pediatric cardiopulmonary resuscitation. PCCM. 2009;10(4): 445–51.
- <span id="page-17-0"></span>59. Waitzer E, Riley SP, Perreault T, Shevell MI. Neurologic outcome at school entry for newborns treated with extracorporeal membrane oxygenation for noncardiac indications. J Child Neurol. 2009;24(7):801–6.
- 60. Schiller RM, Madderom MJ, Reuser JJ, Steiner K, Gischler SJ, Tibboel D, et al. Neuropsychological follow-up after neonatal ECMO. Pediatrics. 2016;138(5):e20161313.
- 61. Bembea MM, Felling R, Anton B, Salorio CF, Johnston MV. Neuromonitoring during extracorporeal membrane oxygenation: a systematic review of the literature. PCCM. 2015;16(6):558–64.
- <span id="page-17-2"></span>62. Kwon HM, Park JH, Kim JM, Yoon BW. Mild left ventricular dysfunction is associated with thrombogenicity in cardioembolic stroke. Eur Neurol. 2006;56(4):217–21.
- <span id="page-17-1"></span>63. Yang Y, Grosset DG, Li Q, Lees KR. Identifcation of echocardiographic "smoke" in a bench model with transcranial doppler ultrasound. Stroke. 2000;31(4):907–14.
- <span id="page-17-3"></span>64. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fbrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J A Soc Echocardiogr. 1999;12(12):1088–96.
- <span id="page-17-4"></span>65. Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, et al. Consensus on microembolus detection by TCD. International consensus group on microembolus detection. Stroke. 1998;29(3):725–9.
- <span id="page-17-5"></span>66. Imaduddin SM, LaRovere KL, Kussman BD, Heldt T. A time-frequency approach for cerebral embolic load monitoring. IEEE Trans Biomed Eng. 2019;67(4):1007–18.
- <span id="page-17-6"></span>67. LaRovere KL, Kapur K, McElhinney DB, Razumovsky A, Kussman BD. Cerebral high-intensity transient signals during pediatric cardiac catheterization: a pilot study using transcranial doppler ultrasonography. J Neuroimaging. 2017;27(4):381–7.
- <span id="page-17-7"></span>68. Sanker P, Roth B, Frowein RA, Firsching R. Cerebral reperfusion in brain death of a newborn. Case report. Neurosurg Rev. 1992;15(4):315–7.
- <span id="page-17-8"></span>69. Glasier CM, Seibert JJ, Chadduck WM, Williamson SL, Leithiser RE Jr. Brain death in infants: evaluation with doppler US. Radiology. 1989;172(2):377–80.
- <span id="page-17-9"></span>70. Bode H, Sauer M, Pringsheim W. Diagnosis of brain death by transcranial doppler sonography. Arch Dis Child. 1988;63(12):1474–8.
- <span id="page-17-10"></span>71. World malaria report 2018. Geneva: World Health Organization; 2018.
- <span id="page-18-0"></span>72. Okiro EA, Al-Taiar A, Reyburn H, Idro R, Berkley JA, Snow RW. Age patterns of severe paediatric malaria and their relationship to plasmodium falciparum transmission intensity. Malar J. 2009;8(4):1–11.
- <span id="page-18-1"></span>73. Taylor TE. Caring for children with cerebral malaria: insights gleaned from 20 years on a research ward in Malawi. Trans R Soc Trop Med Hyg. 2009;103(Suppl 1):S6–10.